Literature DB >> 25899872

Patient Perspectives Associated with Intended Duration of Buprenorphine Maintenance Therapy.

Brandon S Bentzley1, Kelly S Barth2, Sudie E Back3, Garrett Aronson4, Sarah W Book5.   

Abstract

Patients with opioid use disorders frequently discontinue opioid maintenance therapy (OMT) prematurely, reducing retention and possibly limiting the efficacy of OMT. The current study is a cross-sectional survey of patients (N=69) enrolled in buprenorphine maintenance therapy (BMT). We examined patient demographics, BMT characteristics (e.g., dose, time in BMT), and patient perspectives regarding intended duration of BMT. In addition, patients' reasons for continuing or discontinuing BMT were investigated. Results revealed that the majority (82%) of participants reported wanting to continue BMT for at least 12months. Age at first drug use, time in BMT, concern about pain, and concern about relapse were all positively associated with intended duration of BMT. The following were negatively associated with intended duration of BMT: recent discussion with a treatment provider about BMT discontinuation, prior attempt to discontinue BMT, concern about withdrawal symptoms, experiencing pleasurable effects from taking buprenorphine, and perceived conflicts of BMT with life, work, or school obligations. The most common reasons for wanting to continue BMT included concerns about withdrawal symptoms, relapse, and pain. Although preliminary, the findings highlight key issues with regard to patients' perspectives of BMT. The results of this study provide information that may be useful in improving OMT programs and treatment outcomes.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Buprenorphine; Opioid maintenance therapy; Opioid use disorder; Patient perspectives; Treatment cessation

Mesh:

Substances:

Year:  2015        PMID: 25899872      PMCID: PMC4519420          DOI: 10.1016/j.jsat.2015.04.002

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  41 in total

Review 1.  Oral substitution treatment of injecting opioid users for prevention of HIV infection.

Authors:  Linda Gowing; Michael F Farrell; Reinhard Bornemann; Lynn E Sullivan; Robert Ali
Journal:  Cochrane Database Syst Rev       Date:  2011-08-10

2.  Health related quality of life trajectories of patients in opioid substitution treatment.

Authors:  Bohdan Nosyk; Daphne P Guh; Huiying Sun; Eugenia Oviedo-Joekes; Suzanne Brissette; David C Marsh; Martin T Schechter; Aslam H Anis
Journal:  Drug Alcohol Depend       Date:  2011-05-04       Impact factor: 4.492

Review 3.  The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review.

Authors:  Kelly E Dunn; Stacey C Sigmon; Eric C Strain; Sarah H Heil; Stephen T Higgins
Journal:  Drug Alcohol Depend       Date:  2011-07-08       Impact factor: 4.492

4.  Pain and motives for use among non-treatment seeking individuals with prescription opioid dependence.

Authors:  Kelly S Barth; Megan Moran-Santa Maria; Katie Lawson; Stephanie Shaftman; Kathleen T Brady; Sudie E Back
Journal:  Am J Addict       Date:  2013-05-15

5.  A randomized trial of intensive outpatient (IOP) vs. standard outpatient (OP) buprenorphine treatment for African Americans.

Authors:  Shannon Gwin Mitchell; Jan Gryczynski; Robert P Schwartz; Kevin E O'Grady; Yngvild K Olsen; Jerome H Jaffe
Journal:  Drug Alcohol Depend       Date:  2012-09-20       Impact factor: 4.492

Review 6.  Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence.

Authors:  Laura Amato; Silvia Minozzi; Marina Davoli; Simona Vecchi
Journal:  Cochrane Database Syst Rev       Date:  2011-10-05

7.  "Should I stay or should I go?" Coming off methadone and buprenorphine treatment.

Authors:  Adam R Winstock; Nicholas Lintzeris; Toby Lea
Journal:  Int J Drug Policy       Date:  2010-10-16

8.  Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study.

Authors:  Jessica A Dreifuss; Margaret L Griffin; Katherine Frost; Garrett M Fitzmaurice; Jennifer Sharpe Potter; David A Fiellin; Jeffrey Selzer; Mary Hatch-Maillette; Susan C Sonne; Roger D Weiss
Journal:  Drug Alcohol Depend       Date:  2013-01-18       Impact factor: 4.492

9.  A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine.

Authors:  David A Fiellin; Declan T Barry; Lynn E Sullivan; Christopher J Cutter; Brent A Moore; Patrick G O'Connor; Richard S Schottenfeld
Journal:  Am J Med       Date:  2013-01       Impact factor: 4.965

10.  Perceived relapse risk and desire for medication assisted treatment among persons seeking inpatient opiate detoxification.

Authors:  Genie L Bailey; Debra S Herman; Michael D Stein
Journal:  J Subst Abuse Treat       Date:  2013-06-18
View more
  11 in total

1.  Using nominal group technique to identify barriers, facilitators, and preferences among patients seeking treatment for opioid use disorder: A needs assessment for decision making support.

Authors:  Dharushana Muthulingam; Joshua Bia; Lynn M Madden; Scott O Farnum; Declan T Barry; Frederick L Altice
Journal:  J Subst Abuse Treat       Date:  2019-01-26

2.  A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder.

Authors:  Katharine Cioe; Breanne E Biondi; Rebecca Easly; Amanda Simard; Xiao Zheng; Sandra A Springer
Journal:  J Subst Abuse Treat       Date:  2020-09-22

3.  Worries About Discontinuing Buprenorphine Treatment: Scale Development and Clinical Correlates.

Authors:  Michael D Stein; Micah T Conti; Debra S Herman; Bradley J Anderson; Genie L Bailey; Donnell Van Noppen; Ana M Abrantes
Journal:  Am J Addict       Date:  2019-04-16

4.  Neuroinflammation-a co-occurring phenomenon linking chronic pain and opioid dependence.

Authors:  Catherine M Cahill; Anna Mw Taylor
Journal:  Curr Opin Behav Sci       Date:  2017-01-06

5.  Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees.

Authors:  Hillary Samples; Arthur Robin Williams; Mark Olfson; Stephen Crystal
Journal:  J Subst Abuse Treat       Date:  2018-09-07

6.  Patients' Beliefs About Medications are Associated with Stated Preference for Methadone, Buprenorphine, Naltrexone, or no Medication-Assisted Therapy Following Inpatient Opioid Detoxification.

Authors:  Lisa A Uebelacker; Genie Bailey; Debra Herman; Bradley Anderson; Michael Stein
Journal:  J Subst Abuse Treat       Date:  2016-03-09

Review 7.  Cues conditioned to withdrawal and negative reinforcement: Neglected but key motivational elements driving opioid addiction.

Authors:  Caroline B Pantazis; Luis A Gonzalez; Brendan J Tunstall; Stephanie A Carmack; George F Koob; Leandro F Vendruscolo
Journal:  Sci Adv       Date:  2021-04-07       Impact factor: 14.136

8.  Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended-release naltrexone in a residential setting.

Authors:  Paolo Mannelli; Antoine B Douaihy; Sarah C Akerman; Anna Legedza; James Fratantonio; Abigail Zavod; Maria A Sullivan
Journal:  Am J Addict       Date:  2022-02-09

9.  A Research Agenda for Advancing Strategies to Improve Opioid Safety: Findings from a VHA State of the Art Conference.

Authors:  William C Becker; Erin E Krebs; Sara N Edmond; Lewei A Lin; Mark D Sullivan; Roger D Weiss; Adam J Gordon
Journal:  J Gen Intern Med       Date:  2020-11-03       Impact factor: 5.128

Review 10.  Neurobiology of opioid dependence in creating addiction vulnerability.

Authors:  Christopher J Evans; Catherine M Cahill
Journal:  F1000Res       Date:  2016-07-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.